These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26312250)
21. Trends and Challenges in Access to Essential Medicines in Ethiopia and the Contributions of Local Pharmaceutical Production. Marew T; Richmond FJ; Belete A; Gebre-Mariam T Ethiop J Health Sci; 2022 Sep; 32(5):1027-1042. PubMed ID: 36262708 [TBL] [Abstract][Full Text] [Related]
22. Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review. Mirza AH; Alqasomi A; El-Dahiyat F; Babar ZU Integr Pharm Res Pract; 2023; 12():137-155. PubMed ID: 37484573 [TBL] [Abstract][Full Text] [Related]
23. Adverse Impacts of Imposing International Economic Sanctions on Health. Asgardoon MH; Amirzade-Iranaq MH; Mehri A; Piri SM; Jalali P; Ghodsi Z; Dehghan HR; Rahimi-Movaghar V; Salamati P Arch Iran Med; 2022 Mar; 25(3):182-190. PubMed ID: 35429961 [TBL] [Abstract][Full Text] [Related]
24. Economic sanctions threaten population health: the case of Iran. Aloosh M; Salavati A; Aloosh A Public Health; 2019 Apr; 169():10-13. PubMed ID: 30771721 [TBL] [Abstract][Full Text] [Related]
25. Factors influencing the effects of policies and interventions to promote the appropriate use of medicines in high-income countries: A rapid realist review. Charbonneau M; Morgan SG; Gagnon C; Sadowski CA; Silvius JL; Tannenbaum C; Turner JP Health Policy; 2024 Apr; 142():105027. PubMed ID: 38452575 [TBL] [Abstract][Full Text] [Related]
26. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts. Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767 [TBL] [Abstract][Full Text] [Related]
27. Economic crises: some thoughts on why, when and where they (might) matter for health--a tale of three countries. Kaplan GA Soc Sci Med; 2012 Mar; 74(5):643-6. PubMed ID: 22209592 [TBL] [Abstract][Full Text] [Related]
28. A narrative review on problems in product quality, regulatory system constraints, and the concept of quality by design as a solution for quality assurance of African medicines. Hassen HK; Mekasha YT; Tegegne AA; Ozalp Y Front Med (Lausanne); 2024; 11():1472495. PubMed ID: 39421861 [TBL] [Abstract][Full Text] [Related]
29. Protecting pro-poor health services during financial crises: lessons from experience. Gottret P; Gupta V; Sparkes S; Tandon A; Moran V; Berman P Adv Health Econ Health Serv Res; 2009; 21():23-53. PubMed ID: 19791698 [TBL] [Abstract][Full Text] [Related]
30. Effects of the Global Financial Crisis on Health in High-Income Oecd Countries: A Narrative Review. Karanikolos M; Heino P; McKee M; Stuckler D; Legido-Quigley H Int J Health Serv; 2016; 46(2):208-40. PubMed ID: 27076651 [TBL] [Abstract][Full Text] [Related]
31. How economic crises affect alcohol consumption and alcohol-related health problems: a realist systematic review. de Goeij MC; Suhrcke M; Toffolutti V; van de Mheen D; Schoenmakers TM; Kunst AE Soc Sci Med; 2015 Apr; 131():131-46. PubMed ID: 25771482 [TBL] [Abstract][Full Text] [Related]
32. [The effects of economic crises on health care]. Chang NH; Huang CL; Yang YO Hu Li Za Zhi; 2010 Aug; 57(4):89-94. PubMed ID: 20661861 [TBL] [Abstract][Full Text] [Related]
33. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy. Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937 [TBL] [Abstract][Full Text] [Related]
34. The human cost of economic sanctions and strategies for building health system resilience: A scoping review of studies in Iran. Sajadi HS; Yahyaei F; Ehsani-Chimeh E; Majdzadeh R Int J Health Plann Manage; 2023 Sep; 38(5):1142-1160. PubMed ID: 37194133 [TBL] [Abstract][Full Text] [Related]
35. Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries. Ratanawijitrasin S; Soumerai SB; Weerasuriya K Soc Sci Med; 2001 Oct; 53(7):831-44. PubMed ID: 11522132 [TBL] [Abstract][Full Text] [Related]
36. Access to controlled medicines for anesthesia and surgical care in low-income countries: a narrative review of international drug control systems and policies. Nickerson JW; Pettus K; Wheeler KE; Hallam C; Bewley-Taylor DR; Attaran A; Gelb AW Can J Anaesth; 2017 Mar; 64(3):296-307. PubMed ID: 28050803 [TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical policies in European countries in response to the global financial crisis. Vogler S; Zimmermann N; Leopold C; de Joncheere K South Med Rev; 2011 Dec; 4(2):69-79. PubMed ID: 23093885 [TBL] [Abstract][Full Text] [Related]
38. Economic crises and suicides between 1970 and 2011: time trend study in 21 developed countries. Huikari S; Miettunen J; Korhonen M J Epidemiol Community Health; 2019 Apr; 73(4):311-316. PubMed ID: 30692149 [TBL] [Abstract][Full Text] [Related]
39. Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis. Vargas-Pelaez CM; Rover MRM; Soares L; Blatt CR; Mantel-Teeuwisse AK; Rossi FA; Restrepo LG; Latorre MC; López JJ; Bürgin MT; Silva C; Leite SN; Farias MR Int J Equity Health; 2019 Jun; 18(1):68. PubMed ID: 31154999 [TBL] [Abstract][Full Text] [Related]